Clearmind Medici Stock Price, News & Analysis

Clearmind Medicine (NASDAQ: CMND) has announced the enrollment of its first patient in a Phase I/IIa clinical trial for CMND-100, a MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD). The trial, conducted at Yale School of Medicine's Department of Psychiatry and Johns Hopkins University School of Medicine, will evaluate safety, tolerability, and pharmacokinetics, with preliminary efficacy assessments for reducing alcohol cravings. The study targets individuals aged 18-60 who either report heavy binge drinking or are diagnosed with AUD. CEO Dr. Adi Zuloff-Shani highlighted the significant market opportunity, noting that the U.S. substance use disorder treatment market, valued at $35.1 billion in 2021, is projected to reach $60.2 billion by 2029. The company aims to address limitations in current AUD treatments, which have shown limited effectiveness and adverse side effects.

Clearmind Medicine Inc. (NASDAQ: CMND) announces a live webinar titled "Gazing Through the Crystal Ball" scheduled for May 21, 2025, at 12:00 PM ET. The event will feature prominent experts in psychedelic science discussing the evolving landscape of the industry amid changing FDA policies and political climates.

The distinguished panel includes Rick Doblin, Founder and President of MAPS, Robin Carhart-Harris, neuropharmacologist at UCSF, Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine leading the development of CMND-100 for Alcohol Use Disorder, and Mark Haden, VP Business Development at Clearmind. The discussion will be moderated by Shannon Smadella, a social entrepreneur and former MAPS Canada board member.

Clearmind Medicine (NASDAQ: CMND) has announced the publication of a European patent (EP 4531826) for its psychedelic-based combination therapy targeting cocaine addiction. The therapy combines MEAI (5-methoxy-2-aminoindane) with N-Acylethanolamines, including Palmitoylethanolamide (PEA).

Preclinical trials conducted at Bar-Ilan University demonstrated that MEAI significantly reduced cocaine-seeking behavior in animals without affecting their response to natural rewards like sucrose. This suggests the treatment specifically targets drug-related compulsions rather than the general reward system.

The patent publication strengthens Clearmind's intellectual property portfolio and complements similar filings in other markets. The development is part of an ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC) to explore combined MEAI and PEA-based technologies for treating central nervous system disorders.

Clearmind Medicine (Nasdaq: CMND) has filed a new international patent application for treating eating disorders using a combination of 3-Methylmethcathinone (3-MMC) and Palmitoylethanolamide (PEA). The clinical-stage biotech company aims to address the complex factors associated with conditions like anorexia and bulimia.

The announcement highlights the significant global impact of eating disorders, which affect up to 70 million people worldwide. The prevalence has increased from 3.4% to 7.8% between 2000 and 2018, particularly among children and adolescents. These disorders rank among the top ten leading causes of disability among young women and have one of the highest mortality rates among mental disorders.

Clearmind Medicine (NASDAQ: CMND) has completed the initiation of all planned sites for its Phase I/IIa clinical trial in Alcohol Use Disorder (AUD), including the Yale School of Medicine's Department of Psychiatry. The company has secured all necessary preparations, including FDA approval for the Investigational New Drug (IND), Institutional Review Board (IRB) approvals, and the implementation of an Electronic Data Capture (EDC) system.

The trial will be conducted at three locations: Yale School of Medicine led by Dr. Anahita Bassir Nia, Johns Hopkins University School of Medicine, and the IMCA Center in Israel. The study will evaluate CMND-100, the company's drug candidate, which has been successfully manufactured and imported into the United States. The company is now ready to begin patient enrollment for this innovative treatment targeting alcoholism.

Clearmind Medicine Inc. (Nasdaq: CMND) has announced a live webinar titled 'Gazing Through the Crystal Ball' scheduled for May 21, 2025, at 12:00 PM ET. The event will explore the evolving landscape of psychedelic science and business, particularly focusing on FDA policies and political climate changes.

The distinguished panel features notable experts including:

• Rick Doblin, PhD - Founder and President of MAPS
• Robin Carhart-Harris, PhD - Ralph Metzner Distinguished Professor at UCSF
• Dr. Adi Zuloff-Shani - CEO of Clearmind Medicine, leading CMND-100 development for Alcohol Use Disorder
• Mark Haden - VP Business Development and UBC Adjunct Professor

The discussion will be moderated by Shannon Smadella, wellness advocate and podcast host.

Clearmind Medicine (Nasdaq: CMND) has received a Notice of Allowance from the United States Patent Office for a patent covering its MEAI treatment for binge behavior. This development strengthens the company's intellectual property portfolio and provides additional protection for their novel MEAI-based treatment.

The clinical-stage biotech company, which focuses on developing psychedelic-derived therapeutics for major under-treated health problems, views this patent allowance as a important step in supporting their future success and advancing next-generation psychedelic-derived therapeutics aimed at delivering transformative patient outcomes.

Clearmind Medicine (NASDAQ: CMND) has launched its Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived treatment for Alcohol Use Disorder (AUD), at Johns Hopkins University School of Medicine. The trial will also be conducted at Yale School of Medicine and IMCA Center in Israel.

The study aims to evaluate the safety, tolerability, and pharmacokinetics of CMND-100, with preliminary efficacy assessments focusing on alcohol craving and consumption reduction. The trial represents the first clinical application of Clearmind's proprietary MEAI-based oral drug platform.

The study will be led by Jennifer Ellis, PhD, and Professor Eric Strain at Johns Hopkins. This initiative addresses a significant global health challenge, as WHO reports approximately 400 million people suffer from alcohol use disorders, with 209 million experiencing alcohol dependence. Alcohol contributes to 2.6 million deaths annually, representing 4.7% of global deaths, with 13% occurring among those aged 20-39.

Clearmind Medicine (NASDAQ: CMND) has initiated its Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived treatment for Alcohol Use Disorder (AUD), at Johns Hopkins University School of Medicine. The trial will also be conducted at Yale School of Medicine and IMCA Center in Israel.

The study aims to evaluate the safety, tolerability, and pharmacokinetics of CMND-100 in AUD patients, including preliminary efficacy assessments for reducing alcohol cravings and consumption. CMND-100 is a proprietary MEAI-based oral drug candidate designed to modulate reward mechanisms associated with addictive behavior.

The trial's significance is underscored by global AUD statistics: 400 million people aged 15 and older live with alcohol use disorders, with 209 million experiencing alcohol dependence. Alcohol contributes to 2.6 million deaths annually (4.7% of global deaths), with 13% occurring among ages 20-39. In the US, 15.1% of adults aged 18-25 met past-year AUD criteria according to the 2023 NSDUH.